123 related articles for article (PubMed ID: 27647366)
1. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S; Ihalainen J; Forsberg MM; Lehtonen M; Rautio J; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Nov; 24(21):5481-5494. PubMed ID: 27647366
[TBL] [Abstract][Full Text] [Related]
2. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
3. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
[TBL] [Abstract][Full Text] [Related]
5. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
6. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
[TBL] [Abstract][Full Text] [Related]
7. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
[TBL] [Abstract][Full Text] [Related]
8. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
[TBL] [Abstract][Full Text] [Related]
9. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
11. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Feb; 29(3):373-379. PubMed ID: 30587450
[TBL] [Abstract][Full Text] [Related]
12. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
Jasper A; Schepmann D; Lehmkuhl K; Vela JM; Buschmann H; Holenz J; Wünsch B
Eur J Med Chem; 2009 Nov; 44(11):4306-14. PubMed ID: 19709783
[TBL] [Abstract][Full Text] [Related]
14. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists.
Krasavin M; Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Borysko P; Zozulya S; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Nov; 140():229-238. PubMed ID: 28938138
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T
Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733
[TBL] [Abstract][Full Text] [Related]
16. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
17. Ligands at Free Fatty Acid Receptor 1 (GPR40).
Hara T
Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
[TBL] [Abstract][Full Text] [Related]
18. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.
Guba W; Green LG; Martin RE; Roche O; Kratochwil N; Mauser H; Bissantz C; Christ A; Stahl M
J Med Chem; 2007 Dec; 50(25):6295-8. PubMed ID: 18020391
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
